<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388296</url>
  </required_header>
  <id_info>
    <org_study_id>PRH 03</org_study_id>
    <nct_id>NCT01388296</nct_id>
  </id_info>
  <brief_title>Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients</brief_title>
  <official_title>Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procare Riaya Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procare Riaya Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the target of this study is to assess the minimum alveolar concentration of sevoflurane to
      maintain theBispectral Index below 50.The minimum alveolar concentration (MAC) for
      maintaining Bispectral Index below 50 (MACBIS50) of sevoflurane has been reported previously
      in adult with Body Mass Index ( BMI) &lt; 40 to be 0.97 and in enfant to be 2.83%, However,
      there is no study assessed theBispectral Index below 50 (MACBIS50 ) in morbidly obese patient
      (BMI &gt; 40). The first aim of our study is to assess the MACBIS50 of sevoflurane in morbidly
      obese patients BMI 40 - 70 using the Continuous Reassessment Method (CRM) in 80 % of
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After ethical committee approval and written informed consent, 30 morbidly obese adult
      patients , BMI 40- 70Kg/m², ASA physical status 1 and 2 , aged 18-49 yr, , undergoing
      elective bariatric surgery under general anesthesia using sevoflurane, were included in this
      study.

      Monitoring consisted of noninvasive blood pressure, Electrocardiogram (ECG) , pulse oximetry,
      and BIS. All subjects received a standard dose of 2 mcg/kg fentanyl approximately 20 min
      before induction of general anesthesia. a standard BIS® monitor strip was applied before
      fentanyl administration and induction of general anesthesia. Induction was performed in all
      patients with 2m/kg propofol, 0.2 mg/kg cisatracuruim, followed by direct laryngoscopy and
      tracheal intubation. Therefore, when BIS reached &gt; 65 , sevoflurane was started immediately
      at the predetermined dose.

      The endtidal sevoflurane concentration was adjusted with starting dose for the first cohort
      patients 1% and maintained for 10 min to ensure equilibration with the cerebral anesthetic
      partial pressure followed by a 1-min assessment of BIS taken at 10-s intervals. Briefly, a
      first dose is given to the first patient and the next doses are given according to the
      following rule: if the subject responds positively (BIS&lt;50), the dose is decreased one step
      for the next subject, and conversely, if the subject does not respond (BIS&gt;50), the dose is
      increased one step. The dose adjustment is 0.2% for sevoflurane. The CRM is used to calculate
      the dose adjustment for every cohort with the number of patients for every cohort .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal alveolar concentration of Sevoflurane for Maintaining BIS Below 50</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Morbidly obese patients</arm_group_label>
    <description>BMI 40-50 k/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morbidly obese</arm_group_label>
    <description>BMI 50-60 k/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morbidly obeses</arm_group_label>
    <description>BMI 60-70 k/m2</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Bisbectral index (BIS)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Morbidly obese patients weighting BMI 40-70 k/m2
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  morbidly obese patient

          -  BMI 40-70

          -  age : 20-40 year

        Exclusion Criteria:

          -  Age&lt; 20 and &gt; 40

          -  BMI &lt; 40 and &gt; 70

          -  comorbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahed ZEIDAN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Procare Riaya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahed ZEIDAN, MD</last_name>
    <phone>009615409107</phone>
    <email>doczeidan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Procare Riaya Hospital</name>
      <address>
        <city>Al Khobar</city>
        <state>Estern</state>
        <zip>3</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kamal Abdulkhalek, MD</last_name>
      <phone>00966505814754</phone>
      <email>Kamal.abdulkhaleq@procare.com.sa</email>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>July 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Procare Riaya Hospital</investigator_affiliation>
    <investigator_full_name>Ahed ZEIDAN</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

